ARA-290 — 16mg

Tissue-Protective & Neuroregenerative Research Peptide

ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from the three-dimensional structure of erythropoietin (EPO). Unlike EPO, ARA-290 was designed to activate the innate repair receptor (IRR) without stimulating erythropoiesis, making it an important compound in research surrounding tissue protection, inflammation, and nerve repair.

The Science Behind ARA-290

ARA-290 is being investigated for its ability to activate signaling pathways associated with anti-inflammatory responses, tissue protection, neuronal repair, and cellular survival.

Research suggests the innate repair receptor becomes more active following tissue or nerve injury. ARA-290 may help shift the local environment away from inflammatory and tissue-damaging signaling toward processes associated with repair and recovery.

Key Research Areas

• Neuropathic pain research
• Peripheral nerve repair
• Neuroprotection
• Tissue protection
• Inflammatory signaling
• Small-fiber neuropathy
• Neurite growth and regeneration
• Metabolic and vascular research

Neuroregenerative Research

One of the most interesting areas of ARA-290 research is small-fiber neuropathy and nerve regeneration.

In clinical studies involving patients with sarcoidosis-associated small-fiber neuropathy, ARA-290 was associated with improvements in neuropathic and autonomic symptoms, sensory function, quality of life, and measures of corneal nerve fiber density.

A separate Phase 2 study in people with type 2 diabetes and painful neuropathy reported improvements in neuropathic symptoms and certain metabolic measures following 28 days of treatment.

Tissue Protection & Inflammation

Preclinical research has also investigated ARA-290 in models of nerve injury and inflammatory disease. In animal models, activation of the innate repair receptor was associated with reduced neuroinflammatory signaling, improved nerve regeneration, and tissue-protective effects.

The research concept can be summarized as:

ARA-290 → Innate Repair Receptor → Reduced Inflammatory Signaling → Tissue Protection → Neural Repair

Why Researchers Are Interested

ARA-290 is particularly interesting because it represents a different approach to EPO-related biology. Rather than targeting EPO’s classic erythropoietic effects, ARA-290 is designed to investigate the tissue-protective and repair-related signaling associated with the innate repair receptor.

This makes it a compelling research compound for studying nerve health, neuroinflammation, tissue repair, and cellular resilience.

Research Considerations

Human studies have investigated ARA-290, but the clinical evidence remains limited and additional research is needed to establish its long-term efficacy and safety across different conditions. A Phase 2 study used 4 mg daily for 28 days, but that clinical protocol should not be interpreted as a recommended dose for other formulations or research applications.

Research Use Only

This product is supplied for laboratory and research purposes only. ARA-290 is not FDA-approved and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or medical condition.

Stack Science™
Performance. Recovery. Longevity.

For Research Use Only. Not for human consumption.